IssuerAnnouncementDetailsV2Portlet

Actions

Jamjoom Pharmaceuticals Factory Co. Board invites its shareholders to attend the Ordinary General Assembly Meeting the (First Meeting)

4015
JAMJOOM PHARMA
0.00 %
1445/12/07     13/06/2024 16:40:11

Element ListExplanation
Introduction The Board of Directors of Jamjoom Pharmaceuticals Factory Company (“Company”) is pleased to invite its shareholders to attend the Ordinary General Assembly meeting (First Meeting), which is scheduled to be held at six thirty (6:30) PM) on Thursday 04/07/2024G corresponding to 28/12/1445 H from the Company’s headquarter in Jeddah, Online via Tadawulaty Platform (http://tadawulaty.com.sa).
City and Location of the General Assembly's Meeting Online via Tadawulaty Platform at the headquarters of the Company in the city of Jeddah
Hyperlink of the Meeting Location Click Here
Date of the General Assembly's Meeting 2024-07-04 Corresponding to 1445-12-28
Time of the General Assembly’s Meeting 18:30
Methodology of Convening the General Assembly’s Meeting Via modern technology means
Attendance Eligibility, Registration Eligibility, and Voting End The eligibility to attend the meeting is for shareholders registered in the Company share registry at the Depository Center as of the end of trading prior to the Meeting day, and as per the rules and regulations. The shareholders have the right to discuss matters listed in the agenda of the General Assembly and raise relevant questions. The eligibility for Registering the Attendance of the General Assembly’s Meeting Ends upon the conduction of the General Assembly’s Meeting. The eligibility for Voting on the Meeting Agenda Ends upon the concluding counting committee sorting the Votes.
Quorum for Convening the General Assembly's Meeting The Ordinary General Assembly meeting shall be valid if attended by shareholders representing at least a quarter of the capital. If the quorum required for holding this meeting is not fulfilled, the second meeting will be held one hour after the end of the period specified for the first meeting, and the second meeting will be valid regardless of the number of shares represented in it.
General Assembly Meeting Agenda 1.Vote on the remunerations for the members of the Board of Directors and the Committees emanating from the Board of Directors, amounting to 2,324,500 Saudi Riyals for the fiscal year ended 31/12/2023.

2.Vote on the contracts and dealings conducted between the Company and Tegan Al-Fateh Factory Company Limited, in which Board Member Mr. Yousuf Mohammed Salah Jamjoom has an indirect interest. This involves an agreement to provide printing services (small cardboard boxes for medicines) under prevailing commercial terms without preferential benefits, noting that the transaction value for the year 2023 amounted to 20,529,024 Saudi Riyals.

3.Vote on the contracts and dealings conducted between the Company and Dream Sky Travel and Tourism Agency, in which the Chairman of the Board, Mr. Mahmoud Yousuf Jamjoom has an indirect interest. This involves providing travel booking services under prevailing commercial terms without preferential benefits, noting that the transaction value for the year 2023 amounted to 11,244,436 Saudi Riyals.

4.Vote on the contracts and dealings that will be conducted between the Company and Dream Sky Travel and Tourism Agency, in which the Chairman of the Board, Mr. Mahmoud Yousuf Jamjoom has an indirect interest. This involves providing advance payments for the year 2023 for travel booking services under prevailing commercial terms without preferential benefits, noting that the advance payment amounting to 4,553,644 Saudi Riyals has been paid for the year 2023 of which 509,602 Saudi Riyals has been paid for the year 2024.

5.Vote on the contracts and dealings that took place between the Company and Jamjoom Algeria Lildawa, in which the Chairman of the Board Mr. Mahmoud Yousuf Jamjoom, the Vice Chairman of the Board Mr. Ahmed Yousuf Jamjoom, and the Board Member, Mr. Mohammed Yousuf Jamjoom, have an indirect interest. These transactions are for the purpose of operational expenses for the joint venture, under prevailing commercial terms and without preferential benefits, noting that the value of expenses for the year 2023 amounted to 821,147 Saudi Riyals.

Proxy Form
The shareholder right in discussing the assembly agenda topics, asking questions, and exercising the voting right Shareholders are entitled to discuss matters listed in the agenda of the General Assembly and raise relevant questions to the Board members, noting that the voting is free of charge for all Shareholders via: http://tadawulaty.com.sa
Details of the electronic voting on the Assembly’s agenda Shareholders registered in the Tadawulaty services will be able to vote remotely on the assembly’s agenda. Electronic voting will starting at 1:00AM on Sunday 30/06/ 2024G corresponding to 24/12/1445 H and will last until the end of General assembly time. Please note that registration in Tadawulaty services and voting is free of charge for all shareholders Via the following link:

www.tadawulaty.com.sa

Method of Communication in Case of Any Enquiries For any questions, kindly contact the Investor Relations Department during business hours from 09:00 AM to 05:00 PM at:

Tel: +966 12 614 0099 ext. 3313

Mobile: +966 50 985 3577

Email: ir@jamjoompharma.com

Additional Information With regards to agenda item number 4, we would like to clarify to the respected shareholders that this item is the same item listed as item number 20 from the Extraordinary General Assembly (First Assembly) held on 27/11/1445, corresponding to 04/06/2024. The advance payment transactions between the company and Dream Sky Travel and Tourism Agency during the year 2023 amounted to SAR 4,553,644 the majority of which was for services received during the year 2023 in the amount of SAR 4,044,042 which is included in the total transactions that took place in 2023 SAR 11,244,436 as listed in item number 3 of the agenda of this assembly. As a result, the approval required in item number 4 of this assembly is for the amount of SAR 509,602 for services that will be received in 2024.
Attached Documents     

The Capital Market Authority and Saudi Exchange take no responsibility for the contents of this disclosure, make no representations as to its accuracy or completeness, and expressly disclaim any liability whatsoever for any loss arising from, or incurred in reliance upon, any part of this disclosure, and the issuer accepts full responsibility for the accuracy of the information contained in it and confirms, having made all reasonable enquiries, that to the best of their knowledge and belief, there are no other facts or information the omission of which would make the disclosure misleading, incomplete or inaccurate.

Company Performance

JAMJOOM PHARMA
Add To Watchlist
In your Watchlist
Add To Watchlist
Key Parameters
Last Price 0.0
Net Change 0.0 (0.0%)
Value Traded (Sar) 0
Volume Traded 0
See The Company Profile

LoginPortletPopupv2

Actions

AddtoWatchlistv2

Actions

Add to watchlist